PMID- 28418195
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20181202
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 121
IP  - 2
DP  - 2018 Feb
TI  - Association between type 2 diabetes, curative treatment and survival in men with 
      intermediate- and high-risk localized prostate cancer.
PG  - 209-216
LID - 10.1111/bju.13880 [doi]
AB  - OBJECTIVE: To investigate whether curative prostate cancer (PCa) treatment was 
      received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as 
      little is known about the influence of T2DM diagnosis on the receipt of such 
      treatment in men with localized PCa. SUBJECTS AND METHODS: The Prostate Cancer 
      database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 
      2210) for comparison with data on men with PCa only (n = 23 071). All men had 
      intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 
      ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) 
      localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate 
      logistic regression was used to calculate the odds ratios (ORs) for receipt of 
      curative treatment in men with and without T2DM. Overall survival, for up to 8 
      years of follow-up, was calculated both for men with T2DM only and for men with 
      T2DM and PCa. RESULTS: Men with T2DM were less likely to receive curative 
      treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 
      0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM 
      and high-risk PCa who did and did not receive curative treatment, respectively. 
      CONCLUSIONS: Men with T2DM were less likely to receive curative treatment for 
      localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who 
      received curative treatment had substantially higher survival times than those 
      who did not. Some of the survival differences represent a selection bias, whereby 
      the healthiest patients received curative treatment. Clinicians should interpret 
      this data carefully and ensure that individual patients with T2DM and PCa are not 
      under- nor overtreated.
CI  - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John 
      Wiley & Sons Ltd.
FAU - Crawley, Danielle
AU  - Crawley D
AUID- ORCID: 0000-0001-7294-5634
AD  - Division of Cancer Studies, Cancer Epidemiology Group, King's College London, 
      London, UK.
FAU - Garmo, Hans
AU  - Garmo H
AD  - Division of Cancer Studies, Cancer Epidemiology Group, King's College London, 
      London, UK.
FAU - Rudman, Sarah
AU  - Rudman S
AD  - Guy's and St Thomas' NHS Foundation Trust and King's College London's 
      Comprehensive Biomedical Research Centre, London, UK.
FAU - Stattin, Par
AU  - Stattin P
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
AD  - Department of Surgical and Peri-operative Sciences, Urology and Andrology, Umea 
      University, Umea, Sweden.
FAU - Zethelius, Bjorn
AU  - Zethelius B
AD  - Department of Public Health and Geriatric, Uppsala University, Uppsala, Sweden.
AD  - Medical Products Agency, Uppsala, Sweden.
FAU - Holmberg, Lars
AU  - Holmberg L
AD  - Division of Cancer Studies, Cancer Epidemiology Group, King's College London, 
      London, UK.
FAU - Adolfsson, Jan
AU  - Adolfsson J
AD  - Department of Clinical Science, Intervention and Technology, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Van Hemelrijck, Mieke
AU  - Van Hemelrijck M
AD  - Division of Cancer Studies, Cancer Epidemiology Group, King's College London, 
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170517
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
CIN - BJU Int. 2018 Feb;121(2):164-165. PMID: 29359530
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/drug therapy/*mortality
MH  - Dyslipidemias/epidemiology
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Palliative Care/statistics & numerical data
MH  - Prostatectomy/*statistics & numerical data
MH  - Prostatic Neoplasms/*mortality/pathology/*therapy
MH  - Radiotherapy/*statistics & numerical data
MH  - Risk Factors
MH  - Survival Rate
MH  - Sweden/epidemiology
OTO - NOTNLM
OT  - #PCSM
OT  - #ProstateCancer
OT  - curative treatment
OT  - diabetes
OT  - external beam radiotherapy
OT  - prostatectomy
EDAT- 2017/04/19 06:00
MHDA- 2018/03/14 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 10.1111/bju.13880 [doi]
PST - ppublish
SO  - BJU Int. 2018 Feb;121(2):209-216. doi: 10.1111/bju.13880. Epub 2017 May 17.